These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 9890510)

  • 1. Well-characterized biotechnology products: evolving to meet the needs of the 21st century.
    Zoon KC
    Dev Biol Stand; 1998; 96():3-8. PubMed ID: 9890510
    [No Abstract]   [Full Text] [Related]  

  • 2. Definition of a well-characterized biotechnology product.
    Zoon K; Garnick R
    Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531
    [No Abstract]   [Full Text] [Related]  

  • 3. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The quality control of biotechnology products.
    Federici MM
    Biologicals; 1994 Jun; 22(2):151-9. PubMed ID: 7917231
    [No Abstract]   [Full Text] [Related]  

  • 5. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of potency for well characterized biotechnology proteins.
    Finbloom DS
    Dev Biol Stand; 1998; 96():63-4. PubMed ID: 9890518
    [No Abstract]   [Full Text] [Related]  

  • 8. Biologicals and vaccines: regulatory perspectives.
    Petricciani JC
    Dev Biol Stand; 1986; 63():15-9. PubMed ID: 3743903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology: nucleic acid characterization and genetic stability.
    Biologicals; 1993 Mar; 21(1):81-3. PubMed ID: 8217122
    [No Abstract]   [Full Text] [Related]  

  • 10. US biotech prepares to fight generic biologics.
    Reid B
    Nat Biotechnol; 2002 Apr; 20(4):322. PubMed ID: 11923820
    [No Abstract]   [Full Text] [Related]  

  • 11. ASTM lights the way for tissue engineered medical products standards: jump start for combination medical products that restore biological function of human tissues.
    Picciolo GL; Stocum DL
    Stand News; 2001 Jan; 29(1):30-5. PubMed ID: 11833591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CBER status on reform initiatives: industry reactions and comments.
    Page M
    Food Drug Law J; 1997; 52(2):193-6. PubMed ID: 10557559
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic and biochemical factors affecting product consistency: introduction to the issues.
    Seamon KB
    Dev Biol Stand; 1992; 76():63-7. PubMed ID: 1478357
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mastering Biology.
    Hodgson J
    Biotechnology (N Y); 1991 Oct; 9(10):926, 928. PubMed ID: 1367803
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulating recombinant DNA biologics.
    Crouch ML
    Arzneimittelforschung; 1988 Jul; 38(7):947-9. PubMed ID: 3207440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Industry perspective for biotech products.
    Möritz A
    Dev Biol (Basel); 2004; 118():37-44. PubMed ID: 15645671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of biotechnological products: analysis of the expression construct in cell lines used for production of r-DNA derived protein products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():205-8. PubMed ID: 9737397
    [No Abstract]   [Full Text] [Related]  

  • 20. Current regulatory and legal considerations for follow-on biologics.
    Kingham RF; Lietzan E
    Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.